Prolonged esophagitis after primary dysfunction of the pyloric sphincter in the rat and therapeutic potential of the gastric pentadecapeptide BPC 157.
Seven or fourteen days or twelve months after suturing one tube into the pyloric sphincter (removed by peristalsis by the seventh day), rats exhibit prolonged esophagitis with a constantly lowered pressure not only in the pyloric, but also in the lower esophageal sphincter and a failure of both sphincters. Throughout the esophagitis experiment, gastric pentadecapeptide BPC 157 (PL 14736) is given intraperitoneally once a day (10 microg/kg, 10 ng/kg, last application 24 h before assessment), or continuously in drinking water at 0.16 microg/ml, 0.16 ng/ml (12 ml/rat per day), or directly into the stomach 5 min before pressure assessment (a water manometer connected to the drainage port of a Foley catheter implanted into the stomach either through an esophageal or duodenal incision). This treatment alleviates i) the esophagitis (macroscopically and microscopically, at either region or interval), ii) the pressure in the pyloric sphincter, and iii) the pressure in the lower esophageal sphincter (cmH2O). In the normal rats it increases lower esophageal sphincter pressure, but decreases the pyloric sphincter pressure. Ranitidine, given using the same protocol (50 mg/kg, intraperitoneally, once daily; 0.83 mg/ml in drinking water; 50 mg/kg directly into the stomach) does not have an effect in either rats with esophagitis or in normal rats.
Dobric
Ivan
I
Department of Pharmacology, Medical School, University of Zagreb, Croatia.
Drvis
Petar
P
Petrovic
Igor
I
Shejbal
Drazen
D
Brcic
Luka
L
Blagaic
Alenka Boban
AB
Batelja
Lovorka
L
Sever
Marko
M
Kokic
Neven
N
Tonkic
Ante
A
Zoricic
Ivan
I
Mise
Sandro
S
Staresinic
Mario
M
Radic
Bozo
B
Jakir
Ana
A
Babel
Jaksa
J
Ilic
Spomenko
S
Vuksic
Tihomir
T
Jelic
Ivan
I
Anic
Tomislav
T
Seiwerth
Sven
S
Sikiric
Predrag
P
D000818:Animals; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use; D004195:Disease Models, Animal; D049630:Esophageal Sphincter, Lower / Q000187:drug effects / Q000293:injuries / Q000503:physiopathology; D004941:Esophagitis / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D005260:Female; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D007274:Injections, Intraperitoneal; D007441:Intubation, Gastrointestinal; D009129:Muscle Tonus / Q000187:drug effects; D010446:Peptide Fragments / Q000008:administration & dosage / Q000627:therapeutic use*; D011506:Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D011708:Pylorus / Q000187:drug effects* / Q000293:injuries / Q000503:physiopathology; D011899:Ranitidine / Q000008:administration & dosage / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors; D016896:Treatment Outcome
D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D010446:Peptide Fragments; D011506:Proteins; D011899:Ranitidine; C083833:BPC 157